Development of subunit vaccines against severe acute respiratory syndrome

Drugs of Today

Volumn 44, Issue 1, 2008, Pages 63-73

  Du, Lanying ^a,b   He, Yuxian ^b   Jiang, Shibo ^b   Zheng, Bo Jian ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; INACTIVATED VACCINE; RETROVIRUS VECTOR; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS VECTOR;

ANTIBODY TITER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; HISTOPATHOLOGY; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; LONG TERM CARE; MEMORY CELL; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN FUNCTION; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINE PRODUCTION; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; DRUG DESIGN; HUMANS; MEMBRANE GLYCOPROTEINS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 40849120656     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.1.1131830     Document Type: Review

References (91)

1. Zhong, N.S., Zheng, B.J., Li, Y.M. Poon. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003, 362(9393): 1353-8.
2. Skowronski, D.M., Astell, C., Brunham, R.C. et al. Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 2005, 56: 357-81.
3. Rota, P.A., Oberste, M.S., Monroe, S.S. et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300(5624): 1394-9.
4. Marra, M.A., Jones, S.J., Astell, C.R. et al. The Genome sequence of the SARS-associated coronavirus. Science 2003, 300(5624): 1399-404.
5. Ksiazek, T.G., Erdman, D., Goldsmith, C.S. et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003, 348(20): 1953-66.
6. Peiris, J.S., Yuen, K.Y., Osterhaus, A.D., Stohr, K. The severe acute respiratory syndrome. N Engl J Med 2003, 349(25): 2431-41.
7. Limberis, M.P., Wilson, J.M. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci U S A 2006, 103(35): 12993-8.
8. Normile, D. Infectious diseases. Mounting lab accidents raise SARS fears. Science 2004, 304(5671): 659-61.
9. Orellana, C. Laboratory-acquired SARS raises worries on biosafety. Lancet Infect Dis 2004, 4(2): 64.
10. Guan, Y., Zheng, B.J., He, Y.Q. et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003, 302(5643): 276-8.
11. Song, H.D., Tu, C.C., Zhang, G.W. et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A 2005, 102(7): 2430-5.
12. Lau, S.K., Woo, P.C., Li, K.S. et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 2005, 102(39): 14040-5.
13. Li, W., Shi, Z., Yu, M. et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005, 310(5748): 676-9.
14. Chan, K.H., Cheng, V.C., Woo, P.C. et al. Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63. Clin Diagn Lab Immunol 2005, 12(11): 1317-21.
15. Xu, X., Gao, X. Immunological responses against SARS-coronavirus infection in humans. Cell Mol Immunol 2004, 1(2): 119-22.
16. Pearson, H., Clarke, T., Abbott, A., Knight, J., Cyranoski, D. SARS: What have we learned. Nature 2003, 424(6945): 121-6.
17. Subbarao, K., McAuliffe, J., Vogel, L. et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004, 78(7): 3572-7.
18. Vogel, L.N., Roberts, A., Paddock, C.D. et al. Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV). Vaccine 2007, 25(12): 2173-9.
19. Ng, L.F., Hibberd, M.L., Ooi, E.E. et al. A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. BMC Infect Dis 2004, 4: 34.
20. Peng, H., Yang, L.T., Wang, L.Y. et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology 2006, 351(2): 466-75.
21. Peng, H., Yang, L.T., Li, J. et al. Human memory T cell responses to SARS-CoV E protein. Microbes Infect 2006, 8(9-10): 2424-31.
22. Yang, L.T., Peng, H., Zhu, Z.L. et al. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin Immunol 2006, 120(2): 171-8.
23. Tsao, Y.P., Lin, J.Y., Jan, J.T. et al. HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins. Biochem Biophys Res Commun 2006, 344(1): 63-71.
24. Weiss, S.R., Navas-Martin, S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005, 69(4): 635-64.
25. Du, L., Kao, R.Y., Zhou, Y. et al. Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun 2007, 359(1): 174-9.
26. Bosch, B.J., van der Zee, R., de Haan, C.A., Rottier, P.J. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 2003, 77(16): 8801-11.
27. Spiga, O., Bernini, A., Ciutti, A. et al. Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. Biochem Biophys Res Commun 2003, 310(1): 78-83.
28. Holmes, K.V. SARS-associated coronavirus. N Engl J Med 2003, 348(20): 1948-51.
29. Li, W., Moore, M.J., Vasilieva, N. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426(6965): 450-4.
30. Dimitrov, D.S. The secret life of ACE2 as a receptor for the SARS virus. Cell 2003, 115(6): 652-3.
31. Xiao, X., Chakraborti, S., Dimitrov, A.S., Gramatikoff, K., Dimitrov, D.S. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 2003, 312(4): 1159-64.
32. Babcock, G.J., Esshaki, D.J., Thomas, W.D., Jr., Ambrosino, D.M. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 2004, 78(9): 4552-60.
33. Liu, S., Xiao, G., Chen, Y. et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004, 363(9413): 938-47.
34. Kobinger, G.P., Figueredo, J.M., Rowe, T. et al. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine 2007, 25(28): 5220-31.
35. Lip, K.M., Shen, S., Yang, X. et al. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. J Virol 2006, 80(2): 941-50.
36. Keng, C.T., Zhang, A., Shen, S. et al. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. J Virol 2005, 79(6): 3289-96.
37. He, Y., Zhou, Y., Siddiqui, P., Jiang, S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun 2004, 325(2): 445-52.
38. He, Y., Zhou, Y., Liu, S. et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 2004, 324(2): 773-81.
39. Chen, Z., Zhang, L., Qin, C. et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neu tralizing antibodies primarily targeting the receptor binding region. J Virol 2005, 79(5): 2678-88.
40. Zhao, J., Huang, Q., Wang, W., Zhang, Y., Lv, P., Gao, X.M. Identification and characterization of dominant helper T-cell epitopes in the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 2007, 81(11): 6079-88.
41. Okada, M., Okuno, Y., Hashimoto, S. et al. Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. Vaccine 2007, 25(16): 3038-40.
42. Ma, C., Yao, K., Zhou, F., Zhu, M. Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene. Cell Mol Immunol 2006, 3(6): 459-65.
43. Hu, Y., Wen, J., Tang, L. et al. The M protein of SARS-CoV: basic structural and immunological properties. Genomics Proteomics Bioinformatics 2003, 1(2): 118-30.
44. Wang, J., Wen, J., Li, J. et al. Assessment of immunoreactive synthetic peptides from the structural proteins of severe acute respiratory syndrome coronavirus. Clin Chem 2003, 49(12): 1989-96.
45. Yu, H., Jiang, L.F., Fang, D.Y. et al. Selection of SARS-coronavirus-specific B cell epitopes by phage peptide library screening and evaluation of the immunological effect of epitope-based peptides on mice. Virology 2007, 359(2): 264-74.
46. Arbely, E., Khattari, Z., Brotons, G., Akkawi, M., Salditt, T., Arkin, I.T. A highly unusual palindromic transmembrane helical hairpin formed by SARS coronavirus E protein. J Mol Biol 2004, 341(3): 769-79.
47. Zhong, X., Guo, Z., Yang, H. et al. Amino terminus of the SARS coronavirus protein 3a elicits strong, potentially protective humoral responses in infected patients. J Gen Virol 2006, 87(Pt 2): 369-73.
48. Akerstrom, S., Tan, Y.J., Mirazimi, A. Amino acids 15-28 in the ectodomain of SARS coronavirus 3a protein induces neutralizing antibodies. FEBS Lett 2006, 580(16): 3799-803.
49. Qiu, M., Shi, Y., Guo, Z. et al. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect 2005, 7(5-6): 882-9.
50. Qin, E., Shi, H., Tang, L. et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine 2006, 24(7): 1028-34.
51. Kapadia, S.U., Rose, J.K., Lamirande, E., Vogel, L., Subbarao, K., Roberts, A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 2005, 340(2): 174-82.
52. Gao, W., Tamin, A., Soloff, A. et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003, 362(9399): 1895-6.
53. Shi, S.Q., Peng, J.P., Li, Y.C. et al. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization. Mol Immunol 2006, 43(11): 1791-8.
54. Tsunetsugu-Yokota, Y., Ato, M., Takahashi, Y. et al. Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses. Jpn J Infect Dis 2007, 60(2-3): 106-12.
55. Spruth, M., Kistner, O., Savidis-Dacho, H. et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 2006, 24(5): 652-61.
56. See, R.H., Zakhartchouk, A.N., Petric, M. et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 2006, 87(Pt 3): 641-50.
57. Zhou, J., Wang, W., Zhong, Q. et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 2005, 23(24): 3202-9.
58. Qu, D., Zheng, B., Yao, X. et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine 2005, 23(7): 924-31.
59. Kim, T.W., Lee, J.H., Hung, C.F. et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 2004, 78(9): 4638-45.
60. Zhao, P., Cao, J., Zhao, L.J. et al. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology 2005, 331(1): 128-35.
61. Hu, H., Lu, X., Tao, L. et al. Induction of specific immune responses by SARS-CoV spike DNA vaccine with or without interleukin-2 immunization using different immune routes in mice. Clin Vaccine Immunol 2007, 14(7): 894-901.
62. Yang, Z.Y., Kong, W.P., Huang, Y. et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004, 428(6982): 561-4.
63. Huang. J., Ma, R., Wu, C.Y. Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses. Vaccine 2006, 24(23): 4905-13.
64. Kitabatake, M., Inoue, S., Yasui, F. et al. SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus. Vaccine 2007, 25(4): 630-7.
65. Buchholz, U.J., Bukreyev, A., Yang, L. et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A 2004, 101(26): 9804-9.
66. Ishii, K., Hasegawa, H., Nagata, N. et al. Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. Virology 2006, 351(2): 368-80.
67. Du. L., He, Y., Wang, Y. et al. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. Virology 2006, 353(1): 6-16.
68. Bisht, H., Roberts, A., Vogel, L., Subbarao, K., Moss, B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 2005, 334(2): 160-5.
69. Zhou, Z., Post, P., Chubet, R. et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 2006, 24(17): 3624-31.
70. He, Y., Li, J., Heck, S., Lustigman, S., Jiang, S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol 2006, 80(12): 5757-67.
71. Du, L., Zhao, G., He, Y. et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 2007, 25(15): 2832-8.
72. Zakhartchouk, A.N., Sharon, C., Satkunarajah, M. et al. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine. Vaccine 2007, 25(1): 136-43.
73. Pang, H., Liu, Y., Han, X. et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: Implications for the design of an effective protein-based vaccine. J Gen Virol 2004, 85(Pt 10): 3109-13.
74. Marshall, E., Enserink, M. Medicine. Caution urged on SARS vaccines. Science 2004, 303(5660): 944-6.
75. Sheets, R.L., Stein, J., Manetz, T.S. et al. Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. Toxicol Sci 2006, 91(2): 620-30.
76. Zakhartchouk, A.N., Viswanathan, S., Mahony, J.B., Gauldie, J., Babiuk, L.A. Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice. J Gen Virol 2005, 86(Pt 1): 211-5.
77. Yang, Z.Y., Wyatt, L.S., Kong, W.P., Moodie, Z., Moss, B., Nabel, G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003, 77(1): 799-803.
78. Zhi, Y., Figueredo, J., Kobinger, G.P. et al. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 2006, 17(5): 500-6.
79. Czub, M., Weingartl, H., Czub, S., He, R., Cao, J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 2005, 23(17-18): 2273-9.
80. Weingartl, H., Czub, M., Czub, S. et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associat ed with enhanced hepatitis in ferrets. J Virol 2004, 78(22): 12672-6.
81. Pei, H., Liu, J., Cheng, Y. et al. Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination. Appl Microbiol Biotechnol 2005, 68(2): 220-7.
82. Liu, S.J., Leng, C.H., Lien, S.P. et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine 2006, 24(16): 3100-8.
83. Kam, Y.W., Kien, F., Roberts, A. et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 2007, 25(4): 729-40.
84. Lee, J.S., Poo, H., Han, D.P. et al. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol 2006, 80(8): 4079-87.
85. Jiang, S., He, Y., Liu, S. SARS vaccine development. Emerg Infect Dis 2005, 11(7): 1016-20.
86. He, Y., Jiang, S. Vaccine design for severe acute respiratory syndrome coronavirus. Viral Immunol 2005, 18(2): 327-32.
87. He, Y., Lu, H., Siddiqui, P., Zhou, Y., Jiang, S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005, 174(8): 4908-15.
88. He, Y., Li, J., Li, W., Lustigman, S., Farzan, M., Jiang, S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 2006, 176(10): 6085-92.
89. Woo, P.C., Lau, S.K., Tsoi, H.W. et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 2005, 23(42): 4959-68.
90. Taylor, D.R. Obstacles and advances in SARS vaccine development. Vaccine 2006, 24(7): 863-71.
91. Silva, D.G., Cooper, P.D., Petrovsky N. Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunol Cell Biol 2004, 82(6): 611-6.